A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)
← catalyst calendarNCT07561294 · readout in 812 d
Sponsored by ModernaTX, Inc. (industry) · MRNA — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Single · Prevention
Enrollment
366actual
Sites
8
Country
Canada
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-29 | actual | When the study began enrolling |
| Primary completion | 2028-11-09 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-11-09 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Lyme Disease
Interventions
- Biological: mRNA-1982
- Biological: Placebo
Primary outcomes
what the primary-completion date above is the date OFBoth Phases: Number of Participants with Solicited Local and Systemic Adverse Reactions
measured Day 1 up to Day 7 (7 days post-injection)
Both Phases: Number of Participants with Unsolicited Adverse Events
measured Day 1 up to Day 28 (28 days post-injection)
Both Phases: Number of Participants with Medically Attended Adverse Events, Adverse Events of Special Interest, Serious Adverse Events, and Adverse Events Leading to Discontinuation
measured Day 1 up to Month 21 (End of study)
Permalink · MRNA's whole pipeline · Catalyst calendar · Every registered study · What changed